Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

Published:2018-08 Issue:8 Volume:13 Page:1106-1112
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lee Hansang,Lee Ho Yun,Sun Jong-Mu,Lee Se-Hoon,Kim Youjin,Park Song Ee,Ahn Jin Seok,Park Keunchil,Ahn Myung-Ju

Funder

Ministry of Health and Welfare, Republic of Korea

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. The International epidemiology of lung cancer: latest trends, disparities, and tumor characteristics;Cheng;J Thorac Oncol,2016

2. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

4. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science (New York, NY),2004

5. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer;Bonanno;Curr Drug Targets,2011

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the Efficacy of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor in Patients With EGFR Exon 21 L858R Point Mutation-Positive Non-small Cell Lung Cancer;Cureus;2024-07-18

2. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101);Targeted Oncology;2024-04-13

3. Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease;JTO Clinical and Research Reports;2024-04

4. Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis;Respiratory Medicine Case Reports;2024

5. Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis;Clinical Lung Cancer;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3